Arkolith/Insider Trading/ABOS/Form 4

Meisner Derek M

Chief Legal Officer & Corp SecAcumen Pharmaceuticals, Inc. (ABOS) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$28K
Net Open-Market Flow
-$28K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 27, 2026Option exercise(M)9K$1.85$17K183K
Feb 27, 2026Sell(S)9K$3.01$28K174K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 27, 2026Option exercise(M)9K—$073K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-014365) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML